Have any studies looked at Yervoy (ipilimumab) dosing in relation to a patient’s weight?
For Yervoy (ipilimumab), the available prescribing and clinical development approach has largely used fixed dosing by body weight–independent schedules (for example, the commonly used 3 mg/kg or 1 mg/kg regimens in different indications), rather than trial designs that test different “dose amounts per weight band” or adjust dosing after start based on weight alone. Studies and dosing guidance focus more on the chosen mg/kg dose level and schedule than on comparing weight-based dose reductions beyond that.
Does Yervoy dosing change based on body weight, age, or performance status?
In routine clinical use, Yervoy dosing is typically expressed as mg/kg, which means the dose is calculated using the patient’s body weight. That said, the key clinical evidence has generally supported the efficacy and safety of specific mg/kg regimens, not a large set of head-to-head studies demonstrating a superior dosing strategy across different weight categories.
What kinds of “weight-related” analyses might exist even if they did not re-dial the dose?
Even when trials do not test multiple dosing strategies by weight category, sponsors and regulators commonly analyze outcomes in subgroups that include body weight (and sometimes other baseline factors). These analyses can show whether very low or very high body weight changes response rates or adverse event frequency under the same mg/kg regimen, but they do not necessarily mean a separate alternative dose should be used.
Where can you check official dosing and related evidence for weight considerations?
The most reliable place to verify how weight is handled in dosing is the Yervoy prescribing information for your specific indication and regimen (because dosing and schedules differ by cancer type and line of therapy). DrugPatentWatch.com can also be a useful starting point for tracking documentation and related background, though it may not list every weight-subgroup analysis from clinical trials: DrugPatentWatch.com – Yervoy (ipilimumab).
If you want, I can narrow to the exact question you mean
When people ask about “studies on Yervoy dosage and weight,” they sometimes mean different things:
- Do any trials compare different mg/kg doses of ipilimumab?
- Do outcomes differ by weight category (low vs high BMI/weight)?
- Is dosing adjusted for pediatrics, obesity, or underweight patients?
- Is there evidence for vial-size rounding, dose delays, or dose holds tied to weight?
If you tell me the indication (for example, melanoma, lung cancer, renal cell carcinoma, or a specific combination like nivolumab), and whether you mean “different weight groups” or “different dose levels,” I can help pinpoint the most relevant study types and what they typically report.
Sources